NUVATION BIO INC (NUVB)
US67080N1019 - Common Stock
We assign a fundamental rating of 2 out of 10 to NUVB. NUVB was compared to 191 industry peers in the Pharmaceuticals industry. While NUVB seems to be doing ok healthwise, there are quite some concerns on its profitability. NUVB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
NUVB had negative earnings in the past year.
NUVB had a negative operating cash flow in the past year.
NUVB had negative earnings in each of the past 5 years.
NUVB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -93.12%, NUVB is not doing good in the industry: 76.09% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -105.88%, NUVB is in line with its industry, outperforming 40.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93.12% | ||
| ROE | -105.88% | ||
| ROIC | N/A |
ROA(3y)-12.96%
ROA(5y)-19.12%
ROE(3y)-13.36%
ROE(5y)-19.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NUVB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, NUVB has more shares outstanding
Compared to 5 years ago, NUVB has more shares outstanding
NUVB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 6.65 indicates that NUVB is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.65, NUVB belongs to the top of the industry, outperforming 83.70% of the companies in the same industry.
NUVB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NUVB (0.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.65 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NUVB has a Current Ratio of 9.57. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NUVB (9.57) is better than 81.52% of its industry peers.
NUVB has a Quick Ratio of 9.57. This indicates that NUVB is financially healthy and has no problem in meeting its short term obligations.
NUVB's Quick ratio of 9.57 is amongst the best of the industry. NUVB outperforms 81.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.57 | ||
| Quick Ratio | 9.57 |
3. Growth
3.1 Past
NUVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.16%.
EPS 1Y (TTM)-13.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, NUVB will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-551%
EPS Next 2Y-36.93%
EPS Next 3Y-22.98%
EPS Next 5Y16.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NUVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUVB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as NUVB's earnings are expected to decrease with -22.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-36.93%
EPS Next 3Y-22.98%
5. Dividend
5.1 Amount
NUVB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUVATION BIO INC
NYSE:NUVB (1/3/2025, 8:04:01 PM)
After market: 2.95 +0.06 (+2.08%)2.89
+0.3 (+11.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners44.66%
Inst Owner Change22.4%
Ins Owners27.01%
Ins Owner Change1.84%
Market Cap972.69M
Analysts85.45
Price Target6.63 (129.41%)
Short Float %6.31%
Short Ratio6.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-82.25%
Min EPS beat(2)-151.38%
Max EPS beat(2)-13.12%
EPS beat(4)2
Avg EPS beat(4)-23.06%
Min EPS beat(4)-151.38%
Max EPS beat(4)43.89%
EPS beat(8)6
Avg EPS beat(8)-4.36%
EPS beat(12)9
Avg EPS beat(12)-0.38%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-74.05%
EPS NY rev (1m)0%
EPS NY rev (3m)0.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)52.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 449.9 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.93 | ||
| P/tB | 1.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.01
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93.12% | ||
| ROE | -105.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-12.96%
ROA(5y)-19.12%
ROE(3y)-13.36%
ROE(5y)-19.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 35.66% | ||
| Cap/Sales | 8.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.57 | ||
| Quick Ratio | 9.57 | ||
| Altman-Z | 6.65 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.88%
Cap/Depr(5y)1424.33%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-551%
EPS Next 2Y-36.93%
EPS Next 3Y-22.98%
EPS Next 5Y16.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.14%
OCF growth 3YN/A
OCF growth 5YN/A